S-23

Cat. No.:	HY-112257
CAS No.:	1010396-29-8
Molecular Formula:	$C_{18}H_{13}ClF_4N_2O_3$
Molecular Weight:	416.75
Target:	Androgen Receptor
Pathway:	Vitamin D Related/Nuclear Receptor
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (239.95 mM; Need ultrasonic)

Preparing Stock Solutions

Concentration \ Solvent \ Mass	1 mg	5 mg	10 mg
1 mM	2.3995 mL	11.9976 mL	23.9952 mL
5 mM	0.4799 mL	2.3995 mL	4.7990 mL
10 mM	0.2400 mL	1.1998 mL	2.3995 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

S-23 is an orally active selective androgen receptor modulator (SARM) with a K_i of 1.7 nM. S-23 induces androgen receptor (AR)-mediated transcriptional activation in CV-1 cells. S-23 increases prostate, seminal vesicle, and levator ani muscle weights in castrated rats[1][2].

IC_{50} & Target

Ki: 1.7 nM (Androgen receptor)[1]

In Vitro

S-23 induces AR-mediated transcriptional activation in CV-1 cells when used at a concentration of 10 nM[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

By administration of S-23 to castrated animals, androgen-dependent organ weights increased in a dose-dependent manner. The ED_{50} of S-23 in the prostate and levator ani muscle is 0.43 and 0.079 mg/d, respectively[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague Dawley rats (in castrated male rats)[1]

Dosage:	0.01-3 mg
Administration:	S.c.; daily for 14 d
Result:	Androgen-dependent organ weights increased in a dose-dependent manner. At a dose rate as low as 0.1 mg/d, S-23 is able to selectively maintain the weight of the levator ani muscle at the intact control level, whereas its effects on the prostate and seminal vesicles are lower than 30% of those observed in intact controls.

CUSTOMER VALIDATION

- Drug Test Anal. 2021 Oct 29.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Jones A, et al. Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception. Endocrinology. 2009;150(1):38

[2]. Thevis M, et al. Characterization of in vitro generated metabolites of the selective androgen receptor modulators S-22 and S-23 and in vivo comparison to post-administration canine urine specimens. Drug Test Anal. 2010;2(11-12):589-598.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA